New ways of thinking about Alzheimer's disease
Alzheimer’s disease (AD) is highly prevalent, and its incidence is expected to quadruple by 2050.1 It remains virtually untreatable because current medications have little impact on its severity and progression.
Recently, new approaches to assessing cognitive impairment that could be a precursor to AD have been developed by Quest Diagnostics. An Aß 42/40 biomarker ratio can normalize results, reducing inter-patient variability. Once normalized, results with better sensitivity and specificity can lead to a more definitive assessment, when compared to current diagnostic test protocols.
Dr. Nigel Clarke will discuss the advantages of assessing Alzheimer’s disease risk by measurement of the amyloid beta 42/40 ratio, describe an improved LC-MS/MS approach for amyloid beta 42/40 quantitation and apolipoprotein E phenotyping, and discuss the potential advantages of this approach relative to ELISA platforms. He will also review a new, comprehensive “risk assessment score” used to assess a patient’s risk of having Alzheimer’s disease.